Abstract
Everolimus, an mTOR inhibitor, has been shown to improve progression-free survival in patients with hormone receptor-positive metastatic breast cancer receiving exemestane, an aromatase inhibitor. Everolimus has also been found to be an effective treatment for a number of other malignancies. Renal failure in cancer patients receiving everolimus is rare. We report two cases of renal failure requiring hemodialysis in patients with hormone receptor-positive metastatic breast cancer who were receiving everolimus and exemestane.
| Original language | English |
|---|---|
| Pages (from-to) | 129 - 134 |
| Journal | Breast Cancer Management |
| Volume | 4 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2015 |